AstraZeneca has turned to another digital health partner to support its aspirations in chronic kidney disease (CKD), joining ...

To remain relevant in an interconnected ecosystem, biopharma must go beyond optimising yesterday’s markets and begin ...

In summary, although deal volume is down, there are fewer but larger deal sizes. Life sciences companies that can demonstrate ...

After losing ground in commercial clinical trials in recent years, the UK has now turned a corner and is once again taking a ...

In particular, the organisation is unhappy with Kennedy's repeated assertions that Alzheimer's research has been dedicated to ...

While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...

The infant was born with a metabolic disorder called severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, in which the ...

According to the CDC, cases of myocarditis and pericarditis are rare with the vaccines and, in most cases, resolve within a ...

The $8-per-share deal will give Sanofi control of Vigil's VG-3927, an oral drug candidate for Alzheimer's that acts as an ...

Final draft guidance from NICE has backed NHS use of Filspari (sparsentan) for primary immunoglobulin A nephropathy (IgAN), ...

German biopharma company BioNTech has said it will commit up to £1 billion ($1.34 billion) in investment in the UK over the ...

Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new ...